Teva Launches Generic Baraclude Tablets

Teva announced the launch of Entecavir Tablets, the generic version of Bristol-Myers Squibb’s Baraclude.

Entecavir is an antiviral indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients >2 years old with evidence of active viral replication and either evidence of persistent elevations in serum ALT/AST or histologically active disease. Entecavir, a guanosine nucleoside analogue with activity against HBV reverse transcriptase, is efficiently phosphorylated to the active triphosphate form.

RELATED: Hepatitis B Virus Treatments

Entecavir Tablets are available as a 0.5mg strength in 30- and 90-count bottles; and as a 1mg strength in 30-count bottles.

For more information call (888) 838-2872 or visit